重组疫苗市场规模、份额及成长分析（按类型、疾病、最终用户、分销管道和地区）- 2025-2032 年产业预测

重组疫苗市场预计在 2023 年价值为 100.5 亿美元，并从 2024 年的 112 亿美元增长到 2032 年的 265.5 亿美元，预测期内（2025-2032 年）的复合年增长率为 11.4%。

截至 2023 年 10 月，由于基因工程、基因组学和重组 DNA 技术的进步，疫苗市场正在变革时期。传统疫苗主要依赖病原体减毒或惰性暴露策略，正逐渐被实验室开发的创新替代方案所取代。这些新疫苗利用基因筛检技术有效消除与感染疾病相关的风险，提高了疫苗接种过程的有效性和安全性。这一演变标誌着免疫接种的关键时刻，提供了更精准、更有针对性的方法来改善公共卫生结果。将最尖端科技融入疫苗研发，不仅将拓宽市场前景，也将为医疗保健领域的疫苗接种实践树立新的标准。

目录

介绍

• 调查目的
• 研究范围
• 定义

调查方法

• 资讯采购
• 次要和主要资料方法
• 市场规模预测
• 市场假设与限制

执行摘要

• 全球市场展望
• 供需趋势分析
• 细分机会分析

市场动态及展望

• 市场概况
• 市场规模
• 市场动态
  • 驱动因素和机会
  • 限制与挑战
• 波特的分析

主要市场考察

• 关键成功因素
• 竞争程度
• 主要投资机会
• 市场生态系统
• 市场吸引力指数（2024 年）
• PESTEL 分析
• 宏观经济指标
• 价值链分析
• 定价分析

重组疫苗市场规模（按类型）

• 市场概况
• 次单元重组疫苗
• 减毒重组疫苗
• 载体重组疫苗

重组疫苗市场规模（按疾病）

• 市场概况
• 肺炎链球菌感染
• 癌症
• B型肝炎
• 流感
• 二氧化硅
• 其他的

重组疫苗市场规模（以最终用户划分）

• 市场概况
• 孩子们
• 成人
• 老年人

重组疫苗市场规模（依分销管道划分）

• 市场概况
• 医院和药房
• 政府供应商

重组疫苗市场规模

• 北美洲
  • 美国
  • 加拿大
• 欧洲
  • 德国
  • 西班牙
  • 法国
  • 英国
  • 义大利
  • 其他欧洲国家地区
• 亚太地区
  • 中国
  • 印度
  • 日本
  • 韩国
  • 其他亚太地区
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲国家
• 中东和非洲
  • 海湾合作委员会国家
  • 南非
  • 其他中东和非洲地区

竞争资讯

• 前 5 家公司对比
• 主要企业市场定位（2024年）
• 主要市场参与者所采用的策略
• 近期市场趋势
• 公司市场占有率分析（2024 年）
• 主要企业简介
  • 公司详细信息
  • 产品系列分析
  • 公司分部份额分析
  • 收益与前一年同期比较对比（2022-2024 年）

主要企业简介

• Pfizer Inc.（United States）
• GlaxoSmithKline plc（GSK）（United Kingdom）
• Merck & Co., Inc.（United States）
• Moderna, Inc.（United States）
• Novavax, Inc.（United States）
• Johnson & Johnson（United States）
• AstraZeneca plc（United Kingdom）
• Bavarian Nordic A/S（Denmark）
• BioNTech SE（Germany）
• Vaxart, Inc.（United States）
• Transgene SA（France）
• GeoVax Labs, Inc.（United States）
• Vaxcyte, Inc.（United States）
• Green Cross Corporation（GC Biopharma）（South Korea）
• Bharat Biotech International Limited（India）
• Shantha Biotechnics Limited（India）
• Valneva SE（France）
• Inovio Pharmaceuticals, Inc.（United States）
• Sinovac Biotech Ltd.（China）

结论和建议

Recombinant Vaccines Market size was valued at USD 10.05 billion in 2023 and is poised to grow from USD 11.2 billion in 2024 to USD 26.55 billion by 2032, growing at a CAGR of 11.4% during the forecast period (2025-2032).

As of October 2023, the vaccine market is undergoing a transformative shift driven by advancements in genetic engineering, genomics, and recombinant DNA technologies. Traditional vaccines, which primarily utilized exposure strategies through pathogen attenuation or inactivation, are gradually giving way to innovative laboratory-developed alternatives. These new vaccines harness genetic screening techniques to effectively remove the risks associated with infectious diseases, ensuring both efficacy and heightened safety in vaccination processes. This evolution signifies a pivotal moment in immunization, offering a more precise and targeted approach that enhances public health outcomes. The integration of cutting-edge technology into vaccine development not only broadens the market landscape but also sets new standards for immunization practices in the healthcare sector.

Top-down and bottom-up approaches were used to estimate and validate the size of the Recombinant Vaccines market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Recombinant Vaccines Market Segments Analysis

Global Recombinant Vaccines Market is segmented by Type, Disease, End User, Distribution Channel and region. Based on Type, the market is segmented into Subunit recombinant vaccines, Attenuated recombinant vaccines and Vector recombinant vaccines. Based on Disease, the market is segmented into Pneumococcal Disease, Cancer, Hepatitis B, Influenza, DPT and Others. Based on End User, the market is segmented into Pediatric, Adult and Geriatric. Based on Distribution Channel, the market is segmented into Hospital & Retail Pharmacies and Government Suppliers. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Recombinant Vaccines Market

A key driver of growth in the recombinant vaccines market is the widespread use of recombinant technology, which significantly boosts both the effectiveness and safety of vaccines given to patients. This technology allows for the swift and large-scale production of vaccines, reducing the chances of supply shortages. Additionally, recombinant vaccines do not contain infectious viral particles, which decreases the risk of infection and makes them suitable for individuals with weakened immune systems. The advantages of these vaccines have prompted manufacturers to invest in the development of innovative solutions aimed at viral diseases, utilizing advanced DNA technology, genomics, and state-of-the-art biotechnology techniques to create safer and more effective vaccines.

Restraints in the Recombinant Vaccines Market

The growth of the recombinant vaccines market is hindered by multiple challenges, particularly the high cost associated with each dose, which poses a substantial barrier to widespread adoption. Although international organizations are actively working to enhance global vaccination efforts by distributing millions of doses in various regions, the steep price of these vaccines limits accessibility for numerous populations. As a result, despite ongoing initiatives aimed at ensuring equitable distribution, certain areas still struggle to overcome the financial obstacles tied to vaccination. This situation creates significant disparities in vaccine access, ultimately impacting public health outcomes across different demographics.

Market Trends of the Recombinant Vaccines Market

The Recombinant Vaccines market is witnessing significant growth driven by the rising prevalence of infectious diseases and the urgent need for effective immunization strategies, particularly for vulnerable populations such as the elderly and children. Efforts led by international organizations, including UNICEF and PAHO, to ensure the rapid distribution of vaccines in emergency situations have underscored the critical role of recombinant technologies in enhancing vaccine efficacy and accessibility. This trend not only reflects the global commitment to public health but also highlights advancements in vaccine development, which are pivotal in strengthening community immunity and curbing disease outbreaks worldwide.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis

Global Recombinant Vaccines Market Size by Type & CAGR (2025-2032)

• Market Overview
• Subunit recombinant vaccines
• Attenuated recombinant vaccines
• Vector recombinant vaccines

Global Recombinant Vaccines Market Size by Disease & CAGR (2025-2032)

• Market Overview
• Pneumococcal Disease
• Cancer
• Hepatitis B
• Influenza
• DPT
• Others

Global Recombinant Vaccines Market Size by End User & CAGR (2025-2032)

• Market Overview
• Pediatric
• Adult
• Geriatric

Global Recombinant Vaccines Market Size by Distribution Channel & CAGR (2025-2032)

• Market Overview
• Hospital & Retail Pharmacies
• Government Suppliers

Global Recombinant Vaccines Market Size & CAGR (2025-2032)

• North America (Type, Disease, End User, Distribution Channel)
  • US
  • Canada
• Europe (Type, Disease, End User, Distribution Channel)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Type, Disease, End User, Distribution Channel)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Type, Disease, End User, Distribution Channel)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Type, Disease, End User, Distribution Channel)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• Pfizer Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GlaxoSmithKline plc (GSK) (United Kingdom)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co., Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Moderna, Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novavax, Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Johnson & Johnson (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AstraZeneca plc (United Kingdom)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bavarian Nordic A/S (Denmark)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• BioNTech SE (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Vaxart, Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Transgene S.A. (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GeoVax Labs, Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Vaxcyte, Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Green Cross Corporation (GC Biopharma) (South Korea)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bharat Biotech International Limited (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Shantha Biotechnics Limited (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Valneva SE (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Inovio Pharmaceuticals, Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sinovac Biotech Ltd. (China)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations